[ad_1]
Moderna said on Thursday he was developing a unique vaccine that combines a Covid-19 booster dose with an influenza vaccine. The company hopes to eventually add a vaccine against respiratory viruses (RSV) and other respiratory diseases as an annual injection.
“We believe that this is a very big opportunity for us, if we can deploy this dose as a high efficiency annual respiratory booster,” CEO Stefan Bancel said during a presentation to educate investors on drugs in development. “We believe Moderna can be the first to commercialize this important new opportunity,” he added. The company is conducting clinical trials of the RSV vaccine in the elderly.
Moderna vaccine doses
The pharmaceutical company already had several candidate influenza vaccines in development. The new vaccine combines the flu vaccine with the Corona 19 Covid vaccine.
Studying at an early stage
For its part, Novavax said last Wednesday that it had also launched an early-stage study to test its joint flu and Covid vaccine.
Moderna also provided updates on its experience testing an approved COVID vaccine for children aged 6 months to under 12 years old.
Moderna’s vaccine, which received emergency clearance for people 18 and older in the United States in December, is currently under FDA review for use by adolescents and has yet to received official approval.
A competing vaccine from Pfizer Inc and its German partner BioNTech for ages 12 to 15 was officially cleared earlier this year by the U.S. Food and Drug Administration.
Source link
